Credit Courtesy photo The Arrowhead Innovation Fund has announced an investment in TNeuroPharma, a company creating a new blood test to detect Alzheimer’s disease earlier. Founder and CEO Dr. Kristina Trujillo, a New Mexico State University alumna, said this technology also has the potential to lead to future treatment.
TNeuroPharma already has raised over $1.2 million and now AIF will be adding to their growth. Beto Pallares, AIF fund manager, said the early studies by TNeuroPharma have been exciting.
“We want to help the commercialization of this product – and the possible treatment – come to market as fast as possible,” Pallares said.
AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease
- Topline results expected in November 2022
News provided by
Share this article
Share this article
BALTIMORE, April 21, 2021 /PRNewswire/ AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer s Disease (MCI due to AD). The clinical trial, known as HOPE4MCI (NCT03486938), is a 78-week study, randomized, double-blind, placebo controlled study that has enrolled 164 patients across 23 sites in the United States and Canada.
Dementia Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026) The global dementia drugs market was valued at approximately USD 12,736. 06 million in 2020 and is expected to witness a revenue of USD 19,655. 10 million in 2026, with a CAGR of 7. 87% over the forecast period.
April 15, 2021 08:24 ET | Source: ReportLinker ReportLinker Lyon, FRANCE
New York, April 15, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Dementia Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026) - https://www.reportlinker.com/p06062856/?utm source=GNW
The outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology, in January 2021, the population with dementia are at high risk of contracting COVID-19 infection as the cogniti
Biogen Inc : Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
International healthcare pioneers land and expand in Luxembourg House of MedTech for European impact
News Provided By
Share This Article
House of MedTech- Accelerate Impact
Leesa Soulodre, General Partner R3i Ventures & Chief EIR at the House of MedTech
The House of MedTech provides accelerated digital health and medtech commercialisation pathways between the Americas, Asia and Europe.
Our collaboration with the LIH will validate Naluri for obesity prevention, cardiometabolic diseases and mental health. Our new European HQ puts us on a CE Mark approval path for international scale.” President and Co-founder, Dr Jeremy Ting.LUXEMBOURG, April 6, 2021 /EINPresswire.com/ International healthcare pioneers Naluri, Hoppe Alliance, Stemiglobal, Meracle Health, DroneSec, and Viewmind, have landed in the Luxembourg House of MedTech to accelerate their European impact. These pioneers play an active role in the digital transformation of healthcare, working closely with payers, indus